1. 39·0°C versus 38·5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trial
- Author
-
David Nadal, Jochen Roessler, Cécile Adam, Kurt Leibundgut, Marc Ansari, Katrin Scheinemann, Felix Niggli, Michael Zeller, Karin Zimmermann, Oliver Teuffel, Nanette Keller, Roland A. Ammann, Philipp Agyeman, Christa Koenig, Nicolas von der Weid, Bernhard Eisenreich, Nicole Bodmer, Arne Simon, University of Zurich, and Ammann, Roland A
- Subjects
Male ,Pediatrics ,medicine.medical_treatment ,Bacteremia ,Rate ratio ,law.invention ,Body Temperature ,Patient Admission ,0302 clinical medicine ,law ,Neoplasms ,Developmental and Educational Psychology ,Medicine ,Blood culture ,030212 general & internal medicine ,Prospective Studies ,Child ,610 Medicine & health ,ddc:618 ,Cross-Over Studies ,Neoplasms / therapy ,medicine.diagnostic_test ,Ear ,Intensive care unit ,Patient Admission / statistics & numerical data ,Child, Preschool ,Female ,medicine.drug ,medicine.medical_specialty ,Febrile Neutropenia / diagnosis ,Adolescent ,Antineoplastic Agents ,Neutropenia ,Intensive Care Units, Pediatric ,Bacteremia / epidemiology ,03 medical and health sciences ,Sepsis ,030225 pediatrics ,Humans ,Antipyretic ,2735 Pediatrics, Perinatology and Child Health ,Febrile Neutropenia ,Chemotherapy ,3204 Developmental and Educational Psychology ,business.industry ,Antineoplastic Agents / therapeutic use ,Interim analysis ,medicine.disease ,Sepsis / epidemiology ,Transplantation ,10036 Medical Clinic ,Pediatrics, Perinatology and Child Health ,business - Abstract
BACKGROUND Fever in neutropenia is the most frequent complication of chemotherapy for cancer. The temperature limit defining fever used clinically varies. A higher limit can avoid unnecessary diagnoses in patients spontaneously recovering from fever. This trial primarily aimed to determine if a limit of 39·0°C ear temperature is non-inferior to 38·5°C regarding safety. METHODS This cluster-randomised, multiple crossover, non-blinded, non-inferiority trial was done in six Swiss Paediatric Oncology Group centres (clusters) in Switzerland. Patients (aged 1 to
- Published
- 2020
- Full Text
- View/download PDF